6533b7cffe1ef96bd125846a
RESEARCH PRODUCT
A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”
Mjriam CapulaSandra AranđelovićBtissame El HassouniGiovanna L. I. PetriGiovanna L. I. PetriCristina Cornosubject
DrugCancer ResearchClinical pharmacologybusiness.industrymedia_common.quotation_subjectIn vitro toxicologyTumor cellsGeneral MedicineComputational biologyAnticancer drugIn vitrolaw.invention03 medical and health sciences0302 clinical medicineOncologylawIn vivo030220 oncology & carcinogenesisMedicineEarly phasebusinessmedia_commondescription
One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of pre-clinical drug-discovery phases and target validation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-07-01 | Anticancer Research |